Opportunity to invest in drugs for unmet medical needs
Iproteos has demonstrated its capacity to attract risk capital funding and also small investors through equity crowdfunding rounds. Iproteos is socially committed to the development of first-in-class drugs to treat diseases with urgent medical needs and with a high social and economic impact. Currently, the Iproteos pipeline consists of drugs for the treatment of schizophrenia, epilepsy and paediatric cancer.
In 2014, Iproteos was the first Spanish biotech company to launch a crowdfunding campaign.
Iproteos has also secured public funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 642881, from the Catalan Government’s Department for Entrepreneurship and Knowledge (via the ACCIÓ valuation sections), from the Catalan Finance Institute (ICF) through a cofinancing with the European Regional Development Fund (ERDF) through the JEREMIE program, from the Spanish Ministry of Economy and Finance (via the Emplea, Inncorpora, Torres Quevedo, Neotec and ICEX Next programmes), from the Spanish Organisation of Patents and Trademarks (OEPM), and from the Instituto de Crédito Oficial (ICO).
In 2016, Iproteos closed a funding round of 3M €, led by Caixa Capital Risc, and with participation of Kinled Holding and Ascil Biopharm. Iproteos will set aside this injection of capital to the completion of the regulatory preclinical phase of Iproteos' first-in-class drug for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound is one of the few that are being developed around the world to halt and reverse the cognitive impairment caused by this disease.
For further information, please visit the News page on this website.